3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Interventions
Pemetrexed
10
Cisplatin
9
Gemcitabine
8
Nivolumab
5
Ipilimumab
4
Carboplatin
4
niraparib
3
durvalumab
3
Vinorelbine
3
Bevacizumab
3
tremelimumab
2
pembrolizumab
2
olaparib
2
anetumab ravtansine
2
Radiotherapy, Intensity-Modulated
2
Oxaliplatin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorodeoxyglucose F18
2
Cytoreduction Surgical Procedures
2
vandetanib
1
tislelizumab
1
tazemetostat
1
spartalizumab
1
sargramostim
1
ribociclib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma
×
UV1 vaccine
×
Clear all
NCT04300244
2024-02-29
NIPU
Oslo University Hospital
Phase 2
Active not recruiting
118 enrolled